IL165883A0 - Marker genes for determining renal toxicity - Google Patents

Marker genes for determining renal toxicity

Info

Publication number
IL165883A0
IL165883A0 IL16588304A IL16588304A IL165883A0 IL 165883 A0 IL165883 A0 IL 165883A0 IL 16588304 A IL16588304 A IL 16588304A IL 16588304 A IL16588304 A IL 16588304A IL 165883 A0 IL165883 A0 IL 165883A0
Authority
IL
Israel
Prior art keywords
marker genes
renal toxicity
determining renal
determining
toxicity
Prior art date
Application number
IL16588304A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL165883A0 publication Critical patent/IL165883A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL16588304A 2002-07-04 2004-12-20 Marker genes for determining renal toxicity IL165883A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0215509.1A GB0215509D0 (en) 2002-07-04 2002-07-04 Marker genes
PCT/EP2003/007111 WO2004005544A2 (en) 2002-07-04 2003-07-03 Marker genes for determining renal toxicity

Publications (1)

Publication Number Publication Date
IL165883A0 true IL165883A0 (en) 2006-01-15

Family

ID=9939850

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16588304A IL165883A0 (en) 2002-07-04 2004-12-20 Marker genes for determining renal toxicity

Country Status (10)

Country Link
US (1) US20060008804A1 (enExample)
EP (2) EP1925677A3 (enExample)
JP (2) JP2005531321A (enExample)
CN (1) CN1688715A (enExample)
AU (1) AU2003250879B2 (enExample)
BR (1) BR0312405A (enExample)
CA (1) CA2493860A1 (enExample)
GB (1) GB0215509D0 (enExample)
IL (1) IL165883A0 (enExample)
WO (1) WO2004005544A2 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2412734A1 (en) 2000-06-16 2001-12-27 Biogen, Inc. Renal regulatory elements and methods of use thereof
DE60224275T2 (de) 2001-06-01 2008-12-11 Biogen Idec Ma Inc., Cambridge Moleküle und verfahren zur inhibierung der freisetzung von kim-1
AU2003299925B2 (en) 2002-12-30 2011-10-27 Biogen Ma Inc. KIM-1 antagonists and use to modulate immune system
WO2005107793A2 (en) * 2004-05-06 2005-11-17 The Trustees Of Columbia University Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
ES2622467T3 (es) * 2004-12-20 2017-07-06 Antibodyshop A/S Determinación de lipocalina asociada a gelatinasa de neutrófilos (NGAL) como marcador diagnóstico para trastornos renales
CN103751780A (zh) 2005-03-02 2014-04-30 比奥根艾迪克Ma公司 用于治疗th2介导的疾病的kim-1抗体
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20070087387A1 (en) 2005-04-21 2007-04-19 Prasad Devarajan Method for the Early Detection of Renal Disease Using Proteomics
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
ATE539351T1 (de) 2006-05-30 2012-01-15 Antibodyshop As Verfahren zur schnellen beurteilung der schwere eines traumas
EP2064553B2 (en) * 2006-08-07 2023-06-07 Antibodyshop A/S Diagnostic test to exclude significant renal injury
EP2137538B1 (en) 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
CN103399155A (zh) * 2007-03-26 2013-11-20 诺瓦提斯公司 用于监测肾功能的预测性的肾安全性生物标志物和生物标志物标签
US20090104649A1 (en) 2007-06-11 2009-04-23 Garovic Vesna D Markers for preeclampsia
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
CN101910845A (zh) * 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
EP2075343A1 (en) * 2007-12-21 2009-07-01 Gert Mayer A method of diagnosing a progressive disease
EP2279270B1 (en) * 2008-04-15 2014-06-18 Oberbauer, Rainer Markers of acute kidney failure
US7977110B2 (en) 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
ES2341419B1 (es) * 2008-08-14 2011-05-03 Hospital Clinic I Provincial De Barcelona Wnt1 como biomarcador de daño renal.
US8394606B2 (en) * 2008-11-05 2013-03-12 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (NGAL) protein isoforms enriched from urine and recombinant chinese hamster ovary (CHO) cells and related compositions, antibodies, and methods of enrichment, analysis and use
EP2913676A1 (en) * 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5735922B2 (ja) * 2008-11-22 2015-06-17 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
CN102301008B (zh) * 2009-01-19 2015-05-13 生物梅里埃公司 用于确定患者发生医院内感染的易感性以及确立败血性综合征进展的预后的方法
DK2391653T3 (en) * 2009-01-28 2015-02-09 Ind Tech Res Inst Biomarkers associated nephropathy
CA2770189A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting kidney transplant rejection
ES2530866T3 (es) 2009-12-21 2015-03-06 Mayo Foundation Marcador temprano de proteinuria en pacientes tratados con un tratamiento anti-VEGF
AU2010336392B2 (en) 2009-12-23 2014-01-23 Hill's Pet Nutrition, Inc. Compositions and methods for diagnosing and treating kidney disorders in a canine
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP5804629B2 (ja) * 2011-07-29 2015-11-04 株式会社メディクローム 遺伝子発現変動解析による化学物質の毒性評価方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20140074293A (ko) * 2011-09-14 2014-06-17 바스프 에스이 신장 독성을 평가하기 위한 수단 및 방법
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
CN104937095B (zh) * 2012-10-24 2019-06-07 因瑞金公司 肾细胞群及其用途
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP6297676B2 (ja) 2013-05-06 2018-03-20 日立化成株式会社 標的分子を捕捉するためのデバイス及び方法
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
WO2015153860A1 (en) * 2014-04-04 2015-10-08 Somalogic, Inc. Glomerular filtration rate biomarkers and uses thereof
US10712349B2 (en) 2014-04-15 2020-07-14 The Brigham And Women's Hospital, Inc. Circulating KIM-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
WO2015160805A1 (en) * 2014-04-15 2015-10-22 The Brigham And Women's Hospital, Inc. Circulating kim-1 levels for detection of pathologies associated with injury to, or cancer of, the kidney
US10801066B2 (en) 2014-09-05 2020-10-13 American University Of Beirut Determination of risk for development of cardiovascular disease by measuring urinary levels of podocin and nephrin messenger RNA
EP3218521B1 (en) * 2014-11-12 2019-12-25 Hitachi Chemical Co., Ltd. Method for diagnosing organ injury
CN108271422A (zh) 2015-06-25 2018-07-10 株式会社国际电气通信基础技术研究所 基于器官间串扰系统的预测装置及预测程序
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung
CN114778845A (zh) 2016-03-29 2022-07-22 无限生物制药公司 药物组合物或食品组合物及评价活性成分体内效果的方法
EP3438282A4 (en) * 2016-03-29 2020-05-06 Advanced Telecommunications Research Institute International METHOD FOR SCREENING CANDIDATE SUBSTANCES FOR AN ACTIVE COMPONENT TO PREVENT OR TREAT AT LEAST ONE SELECTED DISEASE IN THE KIDNEY HYPOFUNCTION GROUP, CHRONIC KIDNEY DISEASE AND KIDNEY DEFICIENCY
JP7012033B2 (ja) * 2016-06-17 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー インビトロ腎毒性スクリーニングアッセイ
EP3695224A4 (en) * 2017-10-12 2021-12-29 Cedars-Sinai Medical Center Prognosis and progression biomarkers for chronic kidney disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022612A2 (en) * 1994-02-22 1995-08-24 Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with sensitivity to platinum-based drugs
WO1999037757A1 (en) * 1998-01-22 1999-07-29 Administrators Of The Tulane Educational Fund Cubilin protein, dna sequences encoding cubilin and uses thereof
WO2000012760A2 (en) * 1998-08-28 2000-03-09 Incyte Pharmaceuticals, Inc. Toxicological response markers
EP1153137A2 (en) * 1999-02-12 2001-11-14 Phase-1 Molecular Toxicology Inc. High-throughput toxicological testing using cultured organisms and cells
US20010034023A1 (en) * 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
WO2001032928A2 (en) * 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
US20020037508A1 (en) * 2000-01-19 2002-03-28 Michele Cargill Human single nucleotide polymorphisms
EP1290227B1 (en) * 2000-06-05 2009-08-12 Genetics Institute, LLC Compositions, kits, and methods for identification and modulation of type i diabetes
CA2412734A1 (en) * 2000-06-16 2001-12-27 Biogen, Inc. Renal regulatory elements and methods of use thereof
US7214781B2 (en) * 2000-06-21 2007-05-08 Hitachi Chemical Research Center, Inc. Gene markers for lung cancer
CA2395781C (en) * 2000-07-13 2010-04-13 The Johns Hopkins University School Of Medicine Detection and treatment of polycystic kidney disease
WO2002006537A2 (en) * 2000-07-13 2002-01-24 Curagen Corporation Methods of identifying renal protective factors
EP1364049A2 (en) * 2000-07-31 2003-11-26 Gene Logic, Inc. Molecular toxicology modeling
DE10056802B4 (de) * 2000-11-14 2005-06-16 Epigenomics Ag Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
JP2004535776A (ja) * 2001-01-29 2004-12-02 フェイズ − １ モレキュラー トクシコロジー、インコーポレイテッド ラット毒性関連遺伝子及びその使用

Also Published As

Publication number Publication date
CA2493860A1 (en) 2004-01-15
US20060008804A1 (en) 2006-01-12
BR0312405A (pt) 2005-04-26
EP1521847A2 (en) 2005-04-13
CN1688715A (zh) 2005-10-26
JP2005531321A (ja) 2005-10-20
EP1925677A2 (en) 2008-05-28
AU2003250879B2 (en) 2007-07-26
WO2004005544A2 (en) 2004-01-15
AU2003250879A1 (en) 2004-01-23
GB0215509D0 (en) 2002-08-14
EP1925677A3 (en) 2008-07-02
JP2010042019A (ja) 2010-02-25
WO2004005544A3 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
IL165883A0 (en) Marker genes for determining renal toxicity
AU2003294828A8 (en) Specific markers for pancreatic cancer
AU2003281287A8 (en) Toxicity markers
GB0207107D0 (en) Turf image marker
EP1526865A4 (en) COMPOUNDS FOR TARGETING HEPATIC CELLS
AU304007S (en) Dress-making line marker
GB2394697B (en) Marker pens
GB0225360D0 (en) Genetic markers
AP1993A (en) Selection system containing non-antibiotic resistance selection marker
GB0307643D0 (en) Markers
GB2407937B (en) Position locating system
GB2421692B (en) Distance marker
GB0305202D0 (en) Scale inhibitor
GB0223982D0 (en) Marker gene
GB2403931B (en) Marker pens
GB2398877B (en) Scale
GB0307640D0 (en) Markers
IL148158A0 (en) Marker for sign
AU2003900454A0 (en) Dna markers for marbling
GB0303728D0 (en) Toxicity marker
GB0215577D0 (en) Toxicity marker
GB0215575D0 (en) Toxicity marker
GB2402367B (en) Book marker
GB0220879D0 (en) Toxicity markers
GB0300928D0 (en) Surrogate markers